Abstract
Introduction: Antifungal therapy response is typically low in HSCT recipients with aspergillosis. We compared (1) outcomes in POS-treated HSCT and non-HSCT recipients with aspergillosis with those of external controls receiving other antifungal therapy; (2) safety of POS in HSCT and non-HSCT recipients with aspergillosis. Methods: Patients with invasive fungal infections, including HSCT recipients, who were intolerant of or refractory to other antifungal therapy received oral POS 800 mg/d in divided doses in a prospective, open-label, multicenter study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
